Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
General Health Channel
Reported November 20, 2012

Improving Memory In Multiple Sclerosis

 

(Ivanhoe Newswire) – Multiple Sclerosis (MS) is the most common disabling neurological disease of young adults. There are currently 250,000 to 350,000 people in the United States diagnosed with MS. This estimate suggests that approximately 200 new cases are diagnosed every week. Researchers are now running tests on mice to see if a new experimental drug can improve memory in MS patients.
 
MS patients can experience cognitive difficulties, numbness, weakness, loss of balance, blurred vision and slurred speech. MS is believed to be caused by the immune system wrongfully attacking a person's own myelin, a fatty protein that insulates nerves and helps them send electrical signals to control movement, speech and other functions.
 
Johns Hopkins researchers report the successful use of a form of MRI to identify what appears to be a key biochemical marker for cognitive impairment in the brains of people with MS. In follow-up experiments on mice with a rodent form of MS, researchers were able to use an experimental compound to manipulate that same marker and dramatically improve learning and memory.
 
Half of people with MS experience learning and memory problems, for which there is no approved treatment, along with movement abnormalities that characterize the debilitating autoimmune disorder.
 
"We have a potentially novel treatment for cognitive impairment in MS, a devastating condition on the rise that affects at least 400,000 people in the United States," study leader Adam I. Kaplin, M.D., Ph.D., an assistant professor of psychiatry and behavioral sciences and neurology at the Johns Hopkins University School of Medicine was quoted saying.
 
Kaplin cautions that the treatment has so far been used only in mouse models of MS and is years away from clinical trials in people.
 
Nevertheless, he says, the research has the potential to speed development of new drugs to treat cognitive impairment not only in MS patients, but also in patients with Alzheimer's disease and other neurological conditions.
 
MRI images of brain lesions can often tell physicians how much damage the disease is doing to the brain, and those findings often correlate with physical disability. But until now, says Kaplin, there has been no way to correlate these image findings with cognitive impairment.
 
For the study, Kaplin and his colleagues employed magnetic resonance spectroscopy, which uses standard MRI scanners but adds tests to detect and compare various brain chemicals found on the images. The Johns Hopkins team performed the tests on nine occasions on the brains of subjects with MS, focusing on the hippocampus, the brain's learning and memory center, looking at levels of various brain chemicals.
 
Levels of the neurotransmitter N-acetylaspartylglutamate (NAAG), the most abundant peptide transmitter in the brain, stood out. At the same time patients came in for their MRI scan, they completed eight different cognitive tests. The research team found a strong correlation between levels of NAAG in the right hippocampus and performance on six of the eight cognitive tests. The lower the levels of NAAG, the worse the subjects performed.
 
Kaplin notes that the availability of stronger MRI magnets in recent years made the NAAG-related findings possible. Buoyed by the strength of the correlation, Kaplin and his team set about determining if the findings were more than incidental.
 
Kaplin then contacted Barbara S. Slusher, Ph.D., M.A.S., director of the Johns Hopkins Brain Science Institute NeuroTranslational Drug Discovery Program. Slusher and her colleagues had identified novel drugs that could block the breakdown of NAAG into its component parts by inhibiting the enzyme glutamate carboxypeptidase II (GCPII), including 2-PMPA.
 
"For years, this has been a treatment in search of a disease," Slusher was quoted saying.
 
Teaming up with Kristen A. Rahn, Ph.D., a psychiatry instructor at the Johns Hopkins University School of Medicine, the researchers bred mice with the rodent version of MS and treated them with 2-PMPA.
 
"Before we could even consider progressing to human trials with this class of drugs, the key was to show that the finding of reduced NAAG in the brains of MS patients was causally related to, and not just correlated with, their cognitive impairment, and to do this we needed to test this out in an animal model of MS," Rahn was quoted saying.
 
They found that 2-PMPA was able to increase the NAAG levels in the MS mice close to those of a comparative set of mice without the disease.
 
Although the mice still showed physical signs of MS, such as dragging limbs and an inability to run quickly, their learning and memory improved significantly.
 
To test learning and memory, the mice were placed in a maze with one escape hatch but many dead ends. On Day 1, all of the mice wandered around and couldn't find the correct escape hole. By Day 4, healthy mice and mice with MS given 2-PMPA went straight for the hole. They were able to find the hole twice as fast as those mice with MS but no drug.
 
The mice also were tested for fear conditioning, a marker for memory. On Day 1, a tone was played and then the mice were given a mild shock. Four days later, the researchers found that the healthy control mice and mice with MS given 2-PMPA froze in fear much longer when they heard the tone than other mice with untreated MS, indicating a stronger memory.
 
Kaplin says that, historically, researchers have considered potential MS drugs to be failures if they didn't alleviate physical symptoms in the animal model. But while 2-PMPA didn't reduce physical disability, it is worth pursuing as a treatment for its "remarkable" ability to improve learning and memory.
 
Researchers don't know what role NAAG plays in cognition. It is possible, Kaplin says, that simply inhibiting its breakdown and having more of this neurotransmitter improves memory and learning. More studies are needed to elucidate this mechanism.
 
Kaplin says he hopes that pharmaceutical companies will take a renewed interest in the development of drugs like 2-PMPA for cognition improvement in MS and possibly other neurodegenerative diseases. Because 2-PMPA is not orally active, the researchers are working on new nanotechnology-based delivery systems to get the drug to the brain. In addition, Slusher is collaborating with the pharmaceutical company Eisai Inc. to develop new drugs that could be taken by mouth.
 
"We are encouraged that there could be a way to enhance cognition in people with MS," Kaplin concluded. "It's something these patients desperately need."
 
Source: The National Academy of Sciences, November 2012
 
 
Related Articles in Latest Medical News:

[ Back to General Health Channel Home ]

MEDICAL ALERT!
Stay up to date on General Health. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Your Baby DVD
What Every Pregnant Woman Should Know

Happier Woman DVD
25 ways to reduce stress

Forever Young DVD
25 ways to lose 10 years

Feel Good Again DVD
25 ways to STOP THE PAIN

If a treatment you read about here helps you, let us know...Click here!!
Advertisement

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page

Scale
Do you know if you are height-weight proportional?

Find out your Body Mass Index (BMI).

Click Here

How safe are your dietary supplements?

Click here to find out with the FDA's list of supplements and drug interactions.

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News